2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1455

B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome
Abstract Number: 1416

B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis
Abstract Number: 971

B Cell ROCK1 Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity
Abstract Number: 883

B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus
Abstract Number: 1880

Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Abstract Number: 1407

Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis
Abstract Number: 1142

Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study
Abstract Number: 609

Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort
Abstract Number: 2726

Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis
Abstract Number: 2381

Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Abstract Number: 2868

Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
Abstract Number: 2

Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus
Abstract Number: 1453

Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome
Abstract Number: 1626

Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus
Abstract Number: 1650

Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
Abstract Number: 720

Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2040

BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes
Abstract Number: 1189

Baylor Rheumatology Initiative: Developing and Guiding Engagement (BRIDGE) Transition Pathway Creation and Implementation
Abstract Number: 1059

BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo
Abstract Number: 45

bDMARD-experienced Filgotinib-treated Patient Samples Exhibit a Partial Reversion to the Peripheral Molecular Profile of a Demographically Matched Healthy Population
Abstract Number: 2545

Belatacept in Systemic Lupus Erythematosus (SLE) Kidney Transplant Patients
Abstract Number: 1002

Beneficial Effect of Angiotensin Receptor Blocker in a Spondyloarthritis Animal Model
Abstract Number: 22

Beta-2 Glycoprotein I as a DNA- and NET-binding Protein
Abstract Number: 1858

Beta-2-Glycoprotein-I IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 2017

Beyond Genes—a Multi-omic Analysis of Monozygotic Twins Discordant for Rheumatoid Arthritis
Abstract Number: 167

Bioethics for the Rheumatologist: A Needs-Assessment, Curriculum Development, and Knowledge Assessment of Bioethical Topics for Rheumatology Trainees
Abstract Number: 110

Bioinformatics Analysis of Transcriptomics Data Reveals That SRSF1 Is a Novel Molecular Brake for the T Cell Activation Program and Controls Key Cytokine Signaling Genes Implicated in Systemic Lupus Erythematosus
Abstract Number: 683

Biologic Differences Between Type 1 and 2 Lupus
Abstract Number: 1540

Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Abstract Number: 1693

Biological Therapy in Neurobehçet: Multicenter Study of 31 Patients
Abstract Number: 1272

Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study
Abstract Number: 2113

Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever
Abstract Number: 1895

Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
Abstract Number: 11

Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy
Abstract Number: 1767

Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
Abstract Number: 2009

Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Abstract Number: 1889

Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Abstract Number: 724

Biomechanical Properties of Skin for Assessment of Scleroderma: A Systemic Review
Abstract Number: 1080

Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
Abstract Number: 2115

BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants
Abstract Number: 123

Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope
Abstract Number: 1490

Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Abstract Number: 2195

BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
Abstract Number: 2463

Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis
Abstract Number: 2599

Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients
Abstract Number: 1867

Body Composition in Myositis Patients Is Negatively Changed Compared to Healthy Controls and the Changes Are Associated with Disease Activity and Duration, Skeletal Muscle Involvement and Physical Activity and Nutritional Status
Abstract Number: 2068

Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
Abstract Number: 694

Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE
Abstract Number: 273

Bone Health in Lupus: Findings from the Southern California Lupus Registry
Abstract Number: 2222

Bone Health: An Independent Predictor of Coronary Artery Disease
Abstract Number: 904

Bone Manifestations in Gaucher Disease: A Monocentric Study of 128 Patients
Abstract Number: 2221

Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study
Abstract Number: 2304

Bone Microstructure of Patients with Rheumatoid Arthritis: A HR-pQCT Study
Abstract Number: 2207

Bone Mineral Density and Microarchitecture Among Chinese Patients with Rheumatoid Arthritis
Abstract Number: 2440

Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
Abstract Number: 2216

Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
Abstract Number: 1896

Breastfeeding in Women with Rheumatic Diseases
Abstract Number: PP03

Bridging the Gap: Leveraging Social Media to Improve Patient Support; Build a Path to Collaborative Medicine
Abstract Number: 1996

Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast
Abstract Number: 1627

Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Abstract Number: 974

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Abstract Number: 967

Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
Abstract Number: 1903

BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years
Abstract Number: 2477

Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 2295

Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].